Gilgamesh Pharma

News

Ambrosia's sweet $100m round, and other biofinancings

Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.

News

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.

News

Is AbbVie planning an epic Gilgamesh takeover?

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

News

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the

Ambrosia's sweet $100m round, and other biofinancings

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Is AbbVie planning an epic Gilgamesh takeover?

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

PMV cues up filing for first p53-directed cancer therapy

Discover a new era of healthcare panel engagement: Grounded ...

Gilgamesh Pharma

Editor's Picks